Markets
Krystal Biotech Stock Plunges 12%, Wiping Out $1.2 Billion, As Profit Falls Despite $400 Million Buyback
Third-quarter net income fell to $63.1 million on a tax swing, and management pushed back clinical readouts.
Krystal Biotech (KRYS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Third-quarter net income fell to $63.1 million on a tax swing, and management pushed back clinical readouts.
Earnings
A one-time $31.4 million tax benefit in 2025 turned a strong quarter into a profit decline, and a $400 million buyback follows.
Earnings
The gene-therapy maker's operating income rose to $71.1 million, but a year-earlier tax benefit did not repeat.